An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)

Trial Profile

An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease; Psoriasis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms VITALITY
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Jul 2017 Planned End Date changed from 6 Dec 2017 to 30 Dec 2017.
    • 06 Jul 2017 Planned primary completion date changed from 6 Sep 2017 to 30 Dec 2017.
    • 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top